Article Text

Download PDFPDF
Management of myelofibrosis: a survey of current practice in the United Kingdom
  1. Moosa Rashid Qureshi1,
  2. Cathy MacLean2,
  3. Mary Frances McMullin3,
  4. Claire Harrison1
  1. 1Department of Haematology, Guys and St Thomas’ NHS Foundation Trust, Guy's Hospital, London, UK
  2. 2Department of Haematology, University of Cambridge, Cambridge, UK
  3. 3Department of Haematology, Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast, UK
  1. Correspondence to Dr Claire Harrison, Department of Haematology, Guys and St Thomas’ NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; claire.harrison{at}


Aims To investigate the experience of clinicians in the management of patients with myelofibrosis, current treatment options and their utility.

Methods We used an internet-based survey

Results Of 105 respondents (mostly consultants), 79% identified bothersome symptoms as the most common issue to be addressed, while for 19%, lack of efficacy of treatment fell into this category. The survey found that a wide variety of treatments are employed but with poor perceived efficacy.

Conclusions This is the first UK based assessment of management of myelofibrosis. Perspectives may evolve with the inception of novel therapeutics in this field , but clinical guidelines for effective management currently recommend a wide variety of agents and suggest a limited likely success rate.

  • Myelofibros
  • Management
  • Health Services Res

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.